Osteosarcoma is the most common primary bone tumor, but the pathogenesis is not well understood. While cyclooxygeanse-2 (COX-2) is known to be closely associated with tumor growth and metastasis in several kinds of human tumors, the function of COX-2 in osteosarcoma is unclear. Therefore, to investigate the function of COX-2 in osteosarcoma, we established stable cell lines overexpressing COX-2 in U2OS human osteosarcoma cells. COX-2 overexpression as well as prostaglandin E 2 treatment promoted proliferation of U2OS cells. In addition, COX-2 overexpression enhanced mobility and invasiveness of U2OS cells, which was accompanied by increases of matrix metalloproteinase-2 and -9 (MMP-2 and -9) activities. Selective COX-2 inhibitors, NS-398 and celecoxib, inhibited cell proliferation and abrogated the enhanced mobility, invasiveness and MMP activities induced by COX-2 overexpression. These results suggest that COX-2 is directly associated with cell proliferation, migration and invasion in human osteosarcoma cells, and the therapeutic value of COX-2 inhibitors should be evaluated continuously.
Introduction
Osteosarcoma is the most common primary bone tumor generally affecting young people under the age of 20. It occurs usually in long bones such as the femur, tibia and humerus near metaphyseal growth plates. It is a highly metastatic tumor and the most common metastatic site is the lung. Rapid bone growth, exposure to radiation and several genetic predispositions such as RB mutations (hereditary retinoblastoma) or p53 mutations (Li-Fraumeni syndrome) are thought to be risk factors for developing osteosarcoma. However, the exact mechanisms of osteosarcoma development and progression are largely unknown (Longhi et al., 2006) .
Cyclooxygenase-2 (COX-2) is an enzyme catalyzing the conversion of arachidonic acid and O2 to prostaglandin H2, the committed step in prostanoid biosynthesis. The major final end product is prostaglandin E2 (PGE2). COX-2 expression is induced by various stimuli, and the overexpression is closely related to the pathogenesis of some degenerative diseases including cancer (Smith et al., 1996) . Several lines of evidence indicate that COX-2 overexpression can be a causal factor for tumor growth and metastasis. In transgenic mice overexpressing COX-2 in mammary glands develop mammary gland hyperplasia, dysplasia and metastatic tumors (Klein et al., 2005) . Overexpression of COX-2 under a keratin-5 promoter causes transitional cell hyperplasia and carcinoma in urinary bladders of the transgenic mice (Liu et al., 2001 ). In addition, overexpression of COX-2 in vitro promotes cell proliferation in human prostate cancer cells and enhances invasiveness of human bladder, breast and colon cancer cells (Tsujii et al., 1997; Fujita et al., 2002; Li et al., 2002; Singh et al., 2005) .
However, the function of COX-2 in osteosarcoma is unclear. High levels of COX-2 expression have been observed in osteosarcoma tissues, but the correlation between COX-2 expression levels and clinical outcomes has not been found (Dickens et al., 2002 (Dickens et al., , 2003 . Selective COX-2 inhibitors have been reported to inhibit osteosarcoma cell proliferation and invasion in vitro and tumor growth and metastasis in vivo (Sanbino et al., 2002; Naruse et al., 2006) . However, there is no direct evidence elucidating the function of COX-2 in osteosarcoma because COX-2 inhibitors may affect other cellular molecules. Moreover, a recent report that murine COX-2 overexpression in osteosarcoma cells inhibited cell growth via inducing cell cycle arrest and apoptosis raise a question about the function of COX-2 in osteosarcoma (Xu et al., 2006) . Therefore, in an attempt to figure out the COX-2 function in osteosarcoma, we established stable cell lines overexpressing COX-2 in U2OS human osteosarcoma cells. We found that COX-2 overexpression increases cell proliferation rates, mobility and invasiveness and that selective COX-2 inhibitors prevent the effect of COX-2 efficiently.
Materials and Methods

Establishment of stable cell lines
Human COX-2 cDNA was cloned into the pcDNA3 vector containing neo r . U2OS cells were transfected with COX-2/pcDNA3 or empty pcDNA3 using lipofectamine 2000 according to manufacturer's instructions (Life technologies Inc., Grand Island, NY). Transfectants were selected in the presence of geneticin, and individual clones were maintained in DMEM containing FBS (10%), penicillin (100 U/ml), streptomycin (100 U/ml) and geneticin (700 µg/ml).
PGE2 production assay
The amount of PGE2 secreted in the culture medium was determined by ELISA (Assay Designs, Ann Arbor, MI). The production of PGE2 was normalized to protein concentrations.
Western blot analysis
Cells were lysed in RIPA buffer (150 mM NaCl, 100 mM Tris-HCl, 1% Tween-20, 1% sodium deoxycholate and 0.1% SDS) with 0.5 mM EDTA, 1 mM PMSF, 10 µg/ml leupeptin, 10 µg/ml aprotinin and 1 µg/ml pepstatin. Proteins were resolved in SDS-PAGE and transferred to nitrocellulose membranes, which were probed with appropriate antibodies. The immunoreactive protein complexes were detected by enhanced chemiluminescence (Amersham Bioscience, Boston, MA). The specific antibody for COX-2 was obtained from BD Biosciences (San Jose, CA).
FACS analysis
Cells were collected and washed with PBS. The resultant pellets were resuspended in 1 ml of cold PBS. Cold ethanol was added and the mixture was kept at 4 o C for 16 hrs. Cells were permeabilized in reagent consisting of 0.5% Triton X-100, 230 µg/ml RNase A and 50 µg/ml propidium iodide in PBS. Samples were kept at 37 o C for 30 min, followed by flow cytometry analysis (Becton Dickinson FACScan).
Migration assay
Migration assays were performed using two-chamberTranswell (Corning, New York, NY) as described previously (Fujita et al., 2002) . The lower surface of a polycarbonate filter with 8 µm pores was coated with 1 µg/ml bovine collagen IV. Cells were trypsinized and suspended in a serum-free medium containing 1% BSA at a concentration of 2 × 10 4 cells/ml. The cells were placed in the upper chamber and free DMEM was placed in the lower chamber. After 1 hr 40 min at 37 o C, the cells in the upper chamber were wiped off with a cotton swab. The cells on the lower surface of the filter were fixed with cold methanol, stained with 0.2% crystal violet and counted under a light microscope.
Invasion assay
Invasion assays were performed using two-chamberTranswell (Corning, New York, NY) as described previously (Singh et al., 2005) . The upper surface of a polycarbonate filter with 8 µm pores was coated with 1 mg/ml matrigel. Cells were trypsinized and suspended in a serum-free medium containing 1% BSA at a concentration of 2 × 10 4 cells/ml. The cells were placed in the upper chamber and DMEM containing 10% FBS was placed in the lower chamber. After 20 hr incubation at 37 o C, the cells in the upper chamber were wiped off with a cotton swab. The cells on the lower surface of the filter were fixed with cold methanol, stained with 0.2% crystal violet and counted under a light microscope.
Zymography
Conditioned media were collected and subjected to electrophoresis in 10% SDS-polyacrylamide gels containing 1 mg/ml gelatin at 4 o C. The gels were washed with 2.5% Triton X-100 and incubated in a solution containing 50 mM Tris-HCl, 150 mM NaCl, 10 mM CaCl2 and 0.02% NaN3 at 37 o C for 24 hr, followed by Coomasie staining. Ct is a U2OS cell lysate transfected transiently with human COX-2 cDNA and used as a positive control for the expression of COX-2. β -actin was used as a loading control. (B) PGE2 production was increased in U2OS-COX-2 cells compared with in U2OS-pcDNA3 cells. Culture media were collected and analyzed for PGE2 production using enzyme-linked immunosorbent assay. Error bars indicate means ± SD of two independent experiments with duplicate plates. *P < 0.001 by a Mann-Whitney U-test. Error bars indicate means ± SD of two independent experiments with duplicate plates. *P < 0.001 by a Mann-Whitney U-test. (B) U2OS cells were cultured for the indicated times in the presence or absence of 1 nM PGE2 and the cell number was counted on a hemocytometer under a light microscope. Error bars indicate means ± SD of two independent experiments with duplicate plates. *P < 0.05, **P < 0.001 by a t-test.
Statistical analysis
Statistical differences were analyzed by the paired t-test for paired two-group comparisons and by the Mann-Whitney U-test for independent two group comparisons. Data is expressed as means ± S.D. A significant value was defined as P < 0.05.
Results
COX-2 overexpression in U2OS cells promotes cell proliferation
To investigate the function of COX-2 in osteosarcoma, we established stable human COX-2-overexpressing cell lines in U2OS human osteosarcoma cells. To avoid clonal variations, we established three stable COX-2-overexpressing cell lines (U2OS-COX-2) and three control cell lines (U2OS-pcDNA3). High levels of COX-2 expression were observed by western blot analysis in U2OS-COX-2 cells whereas the expression was barely detectable in U2OS-pcDNA3 cells ( Figure 1A ). PGE 2 secretion was detected in U2OS-pcDNA3 cells, of which the levels were 4-fold higher in U2OS-COX-2 cells ( Figure 1B) . These data suggest that U2OS cells have low levels of COX-2 activity, which was enhanced by stable COX-2 transfection.
When we cultured the stable cell lines, we first observed that cell proliferation rates were increased significantly in U2OS-COX-2 cells as compared with in U2OS-pcDNA3 cells (Figure 2A) . To identify the underlying mechanisms, we analyzed the cell proliferation rates in the presence or absence of PGE 2 , the major end product of COX-2. When we treated U2OS cells with PGE 2 , cell proliferation rates were increased significantly ( Figure 2B ). These results suggest that the catalytic activity of COX-2 is responsible for the growth-promoting effect of COX-2 in U2OS cells. cells were cultured in the presence or absence of NS-398 (A) and celecoxib (B) for 11 days and 8 days, respectively, and the cell number was counted on a hemocytometer under a light microscope. Error bars indicate means ± SD of two independent experiments with duplicate plates. *P < 0.001 by a t-test; compared with the corresponding DMSO-treated cells. NS-398 (C) and celecoxib (D) inhibited PGE2 production in U2OS-COX-2 and U2OS-pcDNA3 cells. PGE2 levels in culture media were measured and normalized to protein concentrations. Error bars indicate means ± SD of two independent experiments with duplicate plates. *P < 0.001 by a t-test; compared with the corresponding DMSO-treated cells. (E) PGE2 reverses the growth-inhibiting effect of NS-398 in U2OS-COX-2 cells. 1.5 × 10 4 cells were cultured in the presence or absence of PGE2 (1 nM) with NS-398 (100 µ M) for the indicated times and the cell number was counted on a hemocytometer under a light microscope. Error bars indicate means ± SD of two independent experiments with duplicate plates. *P < 0.001 by a t-test. 
Selective COX-2 inhibitors suppress proliferation of U2OS cells
We next examined the effect of COX-2 inhibitors on the cell proliferation. The treatment of NS-398 and celecoxib, selective COX-2 inhibitors, reduced cell proliferation rates as well as PGE2 production significantly in both U2OS-COX-2 and U2OS-pcDNA3 cells (Figure 3A-D) . In addition, PGE2 treatment reversed the growth-inhibiting effect of NS-398 on U2OS-COX-2 cells ( Figure 3E ). These data strongly suggest that selective COX-2 inhibitors exert their growth-inhibiting effect via inhibition of COX-2 catalytic activity.
Although NS-398 and celecoxib inhibited cell growth, we could observe neither an increase of cell death rates in the trypan blue staining ( Figure 4A ) nor an increase of apoptosis (sub G1) rates in FACS analysis ( Figure 4B ). These results suggest that the inhibitors lowered cell growth rates not via inducing apoptosis but probably via cell cycle arrest.
COX-2 overexpression in U2OS cells increases cell mobility and invasiveness
Since cancer cell mobility is associated with metastatic potential, we next evaluated the effect of COX-2 overexpression on cell mobility. As shown in Figure 5A , cell migration rates were increased in U2OS-COX-2 cells as compared with in U2OS-pcDNA3 cells by about 7 fold. In addition, NS-398 and celecoxib treatment attenuated the COX-2- Figure 6 . Effects of COX-2 overexpression and selective COX-2 inhibitors on invasiveness of U2OS cells. (A) Matrigel invasion abilities were increased in U2OS-COX-2 cells compared with in U2OS-pcDNA3 cells. NS-398 (20 µ M) and celecoxib (1 µ M) decreased the invasiveness in U2OS-COX-2 cells. Invasion assay was performed as described in Materials and Methods. Error bars indicate means ± SD of three independent experiments with duplicate filters. *P < 0.001 by a MannWhitney U-test. **P < 0.001 by a t-test. (B, C) MMP-2 and -9 activity were enhanced in U2OS-COX-2 cells compared with in U2OS-pcDNA3 cells. NS-398 (B) and celecoxib (C) decreased MMP-2 and -9 activity in U2OS-COX-2 cells. Zymography was performed as described in Materials and Methods.
induced cell migration by about 60% ( Figure 5B) . These data clearly demonstrate that COX-2 overexpression in U2OS cells increases cell mobility.
Matrix invasion abilities of cancer cells are associated closely with metastatic potential. We observed that the invasion abilities were about 4-fold higher in U2OS-COX-2 cells as compared with in U2OS-pcDNA3 cells, which was abated by NS-398 and celecoxib treatment ( Figure 6A ). The process of matrix invasion is mediated mainly by matrix metalloproteinases (MMPs). Among them, MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are known to be strongly correlated with metastatic potential of cancer cells (Klein et al., 2004) . We observed that both MMP-2 and MMP-9 activities were enhanced in U2OS-COX-2 cells as compared with in U2OS-pcDNA3 cells, which was attenuated by NS-398 and celecoxib treatment ( Figure 6B and C).
These results suggest that COX-2 overexpression increases matrix invasion abilities of U2OS cells via enhancing MMP-2 and -9 activities.
Discussion
COX-2 has been reported to promote not only cancer cell proliferation in vitro but also tumor growth in vivo. Stable COX-2 transfection to LnCaP human lung cancer cells accelerates cell growth (Fujita et al., 2002) . In addition, when the same numbers of cancer cells are transplanted into nude mice, COX-2 overexpressing cells form the bigger tumor than the control cells do (Chen et al., 2004) . This growthpromoting effect of COX-2 on cancer cells has been thought to result from its catalytic activity because PGE2 also has the growth-promoting effect on cancer cells. In the case of PGE2 treatment, proliferation rates of colon and lung cancer cells are increased via an EP2 receptor/axin/β-catenin signaling pathway and a Ca 2+ -dependent PKC/Erk signaling pathway, respectively (Castellone et al., 2005; Krysan et al., 2005) . According to our study ( Figure  2B , 3A, B, and E), it seems that COX-2 promotes cell growth via its catalytic activity in U2OS cells, too, even though the exact mechanism should be studied further.
There is a recent report that murine COX-2 overexpression using retroviruses in Saos-2 human osteosarcoma cells inhibited cell proliferation via inducing apoptosis (Xu et al., 2006) . However, we observed that U2OS-COX-2 cells proliferated more rapidly than U2OS-pcDNA3 cells did (Figure 2A ) and the apoptotic cells were rare in both U2OS-COX-2 and U2OS-pcDNA3 cells ( Figure 4B ). In addition, PGE2 promoted cell proliferation at a physiological concentration ( Figure 2B ) and reversed the growthinhibitory effect of NS-398 ( Figure 3E ). Moreover, two kinds of selective COX-2 inhibitors showed growth-inhibiting effects concomitantly ( Figure 3A and B). Therefore, we reasoned that COX-2 does promote cell proliferation in U2OS cells.
It is not clear the reason why the above two studies showed different results. One possible ex-planation is the difference in the cellular levels of reactive oxygen species (ROS) due to the different expression levels of COX-2. A COX-2 molecule has a peroxidase active site besides a cyclooxygenase active site (Smith et al., 1996) . When the above Saos-2 cells were infected with retroviruses overexpressing COX-2, intracellular concentrations of ROS increased via peroxidase activity of COX-2. In addition, antioxidants blocked the increase of ROS as well as the increase of apoptosis, whereas NS-398 had no effect on ROS levels and apoptosis rates (Xu et al., 2006) . These data clearly mean that COX-2-derived ROS mediated apoptosis in Saos-2 cells. It is well known that the concentrations of ROS are critical to decide cell fates, that is, proliferation, cell cycle arrest, or apoptosis (Yoon et al., 2002) . For example, low concentrations (3-15 µM) of H2O2 promoted cell proliferation in fibroblasts, medium concentrations (120-150 µM) caused growth arrest, and high concentrations (0.5-1 mM) caused apoptosis (Davies, 1999) . Therefore, the difference in the concentrations of ROS due to the different expression levels of COX-2 might be the reason of the different results.
Accumulating evidence has indicated that COX-2 increases cancer cell mobility and invasiveness through its catalytic activity. Not only COX-2 transfection but also PGE 2 treatment enhances cell migration and invasion in various types of human cancers (Tsujii et al., 1997; Sheng et al., 2001; Li et al., 2002; Han and Wu, 2005; Singh et al., 2005) . Moreover, NS-398 treatment in Hs578 breast cancer cells decreases cell migration and invasion with a reduction of MMP-1, -2, -3, -9 and -11 expression, which is reversed by PGE 2 addition (Larkins et al., 2006) . Considering our results, it seems that the COX-2/PGE 2 /MMP pathway is responsible for the increase of cell mobility and invasiveness in U2OS cells, too.
Osteosarcoma is a highly malignant tumor. While the 5-year survival rate has increased up to 70% in patients with localized disease, the prognosis is very poor and the 5-year survival rate is only 20-30% in patients with metastatic disease at diagnosis (Longhi et al., 2006) . Therefore, new therapeutic strategies are necessary to increase survival rates in patients with osteosarcoma. On this regard, we believe our present study establishing a causal relation of COX-2 to cell proliferation, migration, and invasion in osteosarcoma cells will provide a molecular basis for the use of selective COX-2 inhibitors in patients with osteosarcoma.
